May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article discusses various news associated with the U.S. Food and Drug Administration (FDA). It has been informed that patent for Plavix, the world's second-best-selling medicine, has expired and the FDA has given approval for sale of its generic versions. It has been informed that a new manufacturing plant of Bristol-Myers Squibb Co. has been approved by the FDA for producing rheumatoid arthritis drug Orencia.


Related Articles

  • BMS Wins Round in Genetic Battle Blocking Buspirone Market Entry. Krause, Carey // Chemical Market Reporter;3/26/2001, Vol. 259 Issue 13, p16 

    Reports on the victory of Bristol-Myers Squibb on an injunction case preventing the entry of the generic version of BuSpar (buspirone) drug for anti-anxiety. Discussion on the metabolite patent filed in the United States Food and Drug Administration; Sales revenue generated by the buspirone...

  • Sanofi-Aventis/BMS: a Plavix plague on both their houses?  // PharmaWatch: Monthly Review;Mar2006, Vol. 5 Issue 3, p13 

    The article reports that the United States Food and Drug Administration has permitted Canadian generics company Apotex Inc. to launch a generic version of Sanofi-Aventis SA and Bristol-Myers Squibb Co.'s antiplatelet and antithrombotic drug Plavix. The drug has global sales of around $5 billion...

  • CORPORATE.  // MondayMorning;7/29/2013, Vol. 21 Issue 26, p2 

    The article offers news briefs related to the pharmaceutical industry. Drug company Bristol-Myers Squibb Co.'s revenue and profit have been adversely affected by the growing competition in generic drugs. The U.S. Food and Drug Administration (FDA) has cracked down companies that market illegal...

  • Bristol-Myers wins in court, loses in market.  // Dow Theory Forecasts;9/11/2006, Vol. 62 Issue 37, p6 

    The article discusses a court case won by Bristol-Myers Squibb Co. against Apotex Inc. for selling a generic version of its blood thinner Plavix, which was approved by the U.S. Food and Drug Administration in January 2006 and launched on August 8, 2006. It was settled by both companies in March...

  • U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA(r).  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article provides information on the approval of the Bristol-Myers Squibb Co.'s biologics manufacturing facility in Devens, Massachusetts, by the U.S. Food & Drug Administration for commercial production of ORENCIA(®) abatacept. The Devens facility provides increased manufacturing capacity...

  • In Other News.  // Pharmaceutical Representative;Jul2006, Vol. 36 Issue 7, p14 

    The article reports developments related to the pharmaceutical industry in the U.S. Bristol-Myers Squibb Co. has announced its decision to discontinue commercialization of its antibiotic drug Tequin. The Food and Drug Administration (FDA) has cleared Teva Pharmaceuticals USA Inc.'s generic...

  • New orphan drug treats resistant leukemia. LoBuono, Charlotte // Drug Topics;8/7/2006, Vol. 150 Issue 15, p14 

    The article reports on dasatinib as a new drug approved by the United States Food and Drug Administration (FDA). Bristol-Myers Squibb has manufactured the drug under the brand name, Sprycel. Dasatinib is used in the treatment of all phases of chronic myeloid leukemia that is resistant to prior...

  • Bloomberg report.  // Business News New Jersey;1/10/96, Vol. 9 Issue 1, p38 

    Reports on the announcement from Bristol-Myers Squibb stating that the Food and Drug Administration had granted full marketing clearance to the drug Zerit. Use of drug; Submitted new supplemental drug application; Requested expansion on the use of drug; Comments from company's spokeswoman...

  • BMS cited in bulk drug Warning Letter. Dickinson, James G. // Medical Marketing & Media;Aug98, Vol. 33 Issue 8, p36 

    Reports that Bristol-Myers Squibb was cited in a bulk drug Warning Letter issued by the United States Food and Drug Administration (FDA). Allegations brought against Bristol-Myers; Comments from the FDA.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics